Kronos Bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.3
- Today's High:
- $1.39
- Open Price:
- $1.37
- 52W Low:
- $1.19
- 52W High:
- $4.98
- Prev. Close:
- $1.35
- Volume:
- 142650
Company Statistics
- Market Cap.:
- $81.64 million
- Book Value:
- 3.499
- Revenue TTM:
- $3.08 million
- Operating Margin TTM:
- -4146.66%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.56%
- Return on Equity TTM:
- -48.43%
Company Profile
Kronos Bio Inc had its IPO on 2020-10-09 under the ticker symbol KRON.
The company operates in the Healthcare sector and Biotechnology industry. Kronos Bio Inc has a staff strength of 104 employees.
Stock update
Shares of Kronos Bio Inc opened at $1.37 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.3 - $1.39, and closed at $1.31.
This is a -2.96% slip from the previous day's closing price.
A total volume of 142,650 shares were traded at the close of the day’s session.
In the last one week, shares of Kronos Bio Inc have slipped by -6.43%.
Kronos Bio Inc's Key Ratios
Kronos Bio Inc has a market cap of $81.64 million, indicating a price to book ratio of 0.4187 and a price to sales ratio of 0.
In the last 12-months Kronos Bio Inc’s revenue was $3.08 million with a gross profit of $0 and an EBITDA of $-125590000. The EBITDA ratio measures Kronos Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kronos Bio Inc’s operating margin was -4146.66% while its return on assets stood at -26.56% with a return of equity of -48.43%.
In Q2, Kronos Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Kronos Bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kronos Bio Inc’s profitability.
Kronos Bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.7006. Its price to sales ratio in the trailing 12-months stood at 0.
Kronos Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $260.62 million
- Total Liabilities
- $22.06 million
- Operating Cash Flow
- $5.37 million
- Capital Expenditure
- $308000
- Dividend Payout Ratio
- 0%
Kronos Bio Inc ended 2024 with $260.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $260.62 million while shareholder equity stood at $203.34 million.
Kronos Bio Inc ended 2024 with $0 in deferred long-term liabilities, $22.06 million in other current liabilities, 58000.00 in common stock, $-452167000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $44.40 million and cash and short-term investments were $219.46 million. The company’s total short-term debt was $3,038,000 while long-term debt stood at $0.
Kronos Bio Inc’s total current assets stands at $224.12 million while long-term investments were $244000.00 and short-term investments were $175.06 million. Its net receivables were $343000.00 compared to accounts payable of $2.68 million and inventory worth $-343000.00.
In 2024, Kronos Bio Inc's operating cash flow was $5.37 million while its capital expenditure stood at $308000.
Comparatively, Kronos Bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.31
- 52-Week High
- $4.98
- 52-Week Low
- $1.19
- Analyst Target Price
- $10
Kronos Bio Inc stock is currently trading at $1.31 per share. It touched a 52-week high of $4.98 and a 52-week low of $4.98. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $1.7 and 200-day moving average was $1.74 The short ratio stood at 19.93 indicating a short percent outstanding of 0%.
Around 1622.5% of the company’s stock are held by insiders while 5654.2% are held by institutions.
Frequently Asked Questions About Kronos Bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.